UBS Group
TDACW icon

UBS Group’s Translational Development Acquisition Corp Warrants TDACW Stock Holding History

UBS Group’s Portfolio TDACW Stock Details TDACW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,067
Closed -$128 – 11370
2026
Q1 		$128 Hold
1,067
– – ﹤0.01% 10094
2025
Q4 		$299 Sell
1,067
-732
-41% -$240 ﹤0.01% 10049
2025
Q3 		$522 Sell
1,799
-716
-28% -$194 ﹤0.01% 9641
2025
Q2 		$581 Sell
2,515
-225
-8% -$47 ﹤0.01% 9789
2025
Q1 		$384 Buy
+2,740
New +$482 ﹤0.01% 9798

Other funds holding TDACW

Linden Advisors
Linden Advisors New York $19.3B AUM 1.47% 1-Year Est. Return
LMR Partners
LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return
Magnetar Financial
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
AQR Arbitrage
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return
Polar Asset Management Partners
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
Shaolin Capital Management
Shaolin Capital Management Miami, Florida $2.1B AUM 64.05% 1-Year Est. Return
Rivernorth Capital Management
Rivernorth Capital Management West Palm Beach, Florida $2.1B AUM 2.15% 1-Year Est. Return
Tenor Capital Management
Tenor Capital Management New York $7.09B AUM 3.55% 1-Year Est. Return
Alberta Investment Management Corp (AIMCo)
Alberta Investment Management Corp (AIMCo) Edmonton, Alberta, Canada $17.9B AUM 21.9% 1-Year Est. Return

UBS Group's TDACW Position: Q2 2026 in Review

UBS Group sold out of Translational Development Acquisition Corp Warrants (TDACW) in Q2 2026, closing a stake of 1,067 shares — an estimated $128 sold.

UBS Group first reported a position in TDACW in Q1 2025 and held it in 5 quarters. The position peaked at $581 in Q2 2025. 28 funds tracked by Wall St. Rank hold TDACW as of Q2 2026.

  • UBS Group reported no remaining Translational Development Acquisition Corp Warrants position as of Q2 2026 after selling out during the quarter.
  • UBS Group sold 1,067 Translational Development Acquisition Corp Warrants shares in Q2 2026, an estimated $128.
  • UBS Group first reported a position in Translational Development Acquisition Corp Warrants in Q1 2025 and held it in 5 quarters.
  • UBS Group's Translational Development Acquisition Corp Warrants position peaked at $581 in Q2 2025.
  • 28 funds tracked by Wall St. Rank held Translational Development Acquisition Corp Warrants as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.